In order to strengthen its oncology pipeline, Janssen has agreed to pay US$40 M upfront and committed up to US$1.4 B more to access Mersana Therapeutics’ Dolasynthen technology platform to develop antibody-drug conjugate (ADC) candidates for three selected antigen targets. By leveraging Mersana’s platform, the company aims to overcome the limitations posed by existing ADCs. Interestingly, the deal comes shortly after Mersana expanded its collaboration agreement with Synaffix to develop ADC candidates for an additional six targets using the latter’s technology.